Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Erbitux Review Required Six Months Because BLA Was Not Rolling, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency notes speedier reviews are generally a function of an application’s rolling status because the user fee clock does not start until the filing of the application is complete.

You may also be interested in...



Bristol/ImClone's Erbitux Clears FDA; Undergoing Two Confirmatory Trials

Erbitux is indicated for treatment of EGFR-expressing, metastatic colorectal carcinoma in combination with irinotecan or as monotherapy. Launch is expected within two weeks using product manufactured at Lonza Biologics facility.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

CMS Has “Very Robust” Number Of Medicare Part D Bids, McClellan Says

Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.

Topics

UsernamePublicRestriction

Register

PS058601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel